Zydus Lifesciences (BOM:532321) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Debt-to-Equity?

Zydus Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Zydus Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Zydus Lifesciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zydus Lifesciences's Debt-to-Equity or its related term are showing as below:

BOM:532321' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.53 Max: 0.79
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Zydus Lifesciences was 0.79. The lowest was 0.01. And the median was 0.53.

BOM:532321's Debt-to-Equity is ranked better than
99.88% of 851 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs BOM:532321: 0.01

Zydus Lifesciences Debt-to-Equity Historical Data

The historical data trend for Zydus Lifesciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Debt-to-Equity Chart

Zydus Lifesciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.76

0.77

0.36

0.25

0.07

Zydus Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.07	N/A	0.01	N/A

Competitive Comparison of Zydus Lifesciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zydus Lifesciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Debt-to-Equity falls into.

Zydus Lifesciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zydus Lifesciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11751	+	198)	/	175158
	=	0.07

Zydus Lifesciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Zydus Lifesciences (BOM:532321) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zydus Lifesciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences (BOM:532321) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Debt-to-Equity

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines